The DOI matches its Crossref record; 221 of the 226 references it cites were found in a registry or an index; 49 of the 108 sources its claims cite were checked for support.
Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search
Open accessAbstract
Overweight, obesity, and type 2 diabetes mellitus are metabolic health problems and diseases that affect billions of people worldwide. Studies in animals and humans suggest that stimulating global muscle hypertrophy could be a treatment for these diseases, as some key studies suggest that stimulation of global muscle hypertrophy commonly reduces fat mass and improves glucose homeostasis. To analyse the effect of muscle hypertrophy on fat and glucose homeostasis in more detail, we systematically searched the literature and quantitatively analyzed 122 studies (humans: n = 99; animals: n = 23). This analysis reveals that a 1.9–3.3% increase in global muscle mass in humans is associated with 4.1 ± 5.8% lower fat mass, a mean relative reduction in HbA1c of 4.1 ± 4.6% from baseline, and a reduction of fasting glucose concentrations by 5.8 ± 7.3% in studies lasting 2 weeks to 3 years. In the animal studies analyzed, the researchers increased muscle mass by transgenesis, drugs, or resistance training by 17.7 ± 18.4%. This increase of muscle mass was associated with 23.7 ± 22.3% less fat mass. In the second part of this review, we discuss mechanisms by which muscle hypertrophy can affect fat mass and glucose homeostasis. We also discuss the potential use of hypertrophy-focused resistance training and muscle hypertrophy-stimulating drugs as treatments for people with overweight, obesity, and type 2 diabetes.
Overview
CoChat Summary
## TL;DR
This narrative review with a systematic literature search found that global skeletal muscle hypertrophy is associated with lower fat mass and improved glucose homeostasis in both humans and animals. The human evidence was strongest for fat loss and fasting glucose/HbA1c improvements with resistance training, while animal studies more consistently supported a direct link between increased muscle mass and better glucose control.
## Key findings
- The systematic search identified 122 studies total: 99 human and 23 animal intervention studies.
- In human studies, a 1.9–3.3% increase in global muscle mass was associated with 4.1 ± 5.8% lower fat mass, a mean relative HbA1c reduction of 4.1 ± 4.6%, and a 5.8 ± 7.3% reduction in fasting glucose across studies lasting 2 weeks to 3 years.
- For human fat mass, the review reports an overall inverse association between muscle hypertrophy and fat loss (R² = 0.25, r = −0.51, p < 0.001); within subgroups, the association remained significant across BMI, age, and training-experience strata.
- In animal studies, muscle hypertrophy increased muscle mass by 17.7 ± 18.4% and was associated with 23.7 ± 22.3% less fat mass; glucose outcomes showed 16.1 ± 18.7% lower blood glucose overall, though the regression across all animal data was not significant (R² = −0.09, r = −0.10, p = 0.762).
- The paper highlights a human randomized trial of bimagrumab in people with type 2 diabetes and BMI 28–40 kg/m², where lean mass increased by 1.70 kg, fat mass fell by 7.49 kg, and HbA1c decreased by 0.76%.
## Methods
- Narrative review plus systematic literature search using PubMed/MEDLINE, SPORTDiscus, and Scopus on 17 September 2024, with English-language, peer-reviewed studies that induced global muscle hypertrophy in humans, animals, or transgenic models.
- Included studies had to report changes in fat mass or glucose metabolism (HbA1c or blood glucose); the review analyzed 122 studies in total.
- Main analyses were quantitative summaries and linear regressions/correlation analyses relating changes in muscle mass to changes in fat mass or glucose outcomes, with subgroup analyses by BMI, age, and training experience.
## Limitations
- The authors state that they had previously “cherry picked” supportive studies, creating a risk of bias, which is why they conducted the systematic search.
- They note that exercise itself can reduce fat mass and improve glucose homeostasis, making it difficult to disentangle the direct effect of hypertrophy from the effects of training; this limitation is explicitly discussed in the paper.
- The human glucose literature was limited for pharmaceutical-only interventions: only a single human study met the criterion of no exercise component, and the authors report that no regression analyses were performed for that group.
- The paper also makes evident that some interventions act on muscle and adipose tissue simultaneously (for example β-adrenergic agonists and testosterone), which limits causal attribution to muscle hypertrophy alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Muscle building and fat lowering effects of repartitioning agents and myostatin inhibition. A Cross-sections at the 10th rib of pigs [19]. Left represents a pig treated with 3 mg clenbuterol/kg feed for 4 weeks, plus a 3-week course of daily injections of 0.1 mg recombinant porcine growth hormone/kg liveweight. Right represents a typical control animal. B Belgian blue bull showing double muscling and low fat mass. These animals have “natural” mutations of the muscle mass-inhibiting Mstn gene. [Copyright (1997) National Academy of Sciences] [20]](https://figures.cochat.ai/paper-figures/5e18eb18bdb441e194e98e4d5834f648/effects-of-skeletal-muscle-hypertrophy-on-fat-mass-and-glucose-homeostasis-in-figure-1.jpg)


![Fig. 4 Mechanisms that explain the effects of muscle hypertrophy on fat mass and glucose homeostasis. A Akt1 and myostatin are examples of regulators whose action on muscle is enough to cause a loss of fat mass and improvement of glucose homeostasis. B In contrast, the catecholamines adrenaline and noradrenaline, as well β-adrenergic agonists, act both on skeletal muscle and adipose tissue as both tissues express adrenergic receptors. C Inter-organ signal transduction mechanisms (e.g., in response to resistance exercise) versus D metabolic mechanisms (e.g., β-adrenergic agonist effects on skeletal muscle and adipose tissue metabolism; [170]) that can potentially explain the effects of muscle hypertrophy on fat and glucose](https://figures.cochat.ai/paper-figures/42556aebc25c4f6fa29c4512d766c2e3/effects-of-skeletal-muscle-hypertrophy-on-fat-mass-and-glucose-homeostasis-in-figure-4.jpg)
Verification
Claims the paper makes
38 Valid · 2 Not valid · 34 Not checked · 76 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HbA1c was reported in only one study involving myostatin knockout mice, which demonstrated a relative increase in muscle mass of 53.8–59.5% and a corresponding HbA1c reduction of 2.2–21.8% [61].”
§ Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search > Systematic Literature Analysis to Find Out Whether Muscle Hypertrophy Is Associated with Altered Fat Mass and Glucose Homeostasis > Is Muscle Hypertrophy Associated with Altered Glucose Homeostasis?
What the sources say
- Partly supportedcites [61] Butcher JT, Mintz JD, Larion S, Qiu S, Ruan L, Fulton DJ, Stepp DW. Increased muscle mass protects against hypertension and renal injury in obesity. J Am Heart Assoc. 2018;7: e009358. https://doi.org/10.1161/JAHA.118.009358. sourceExperimental — accuracy not yet measured
The Methods and Results passage reports that myostatin deletion increased skeletal muscle mass by approximately 50–60%, and the Results report increases in both lean and obese mice. That supports the stated magnitude, but our copy does not give the precise endpoints of 53.8% and 59.5%. (LLM, conf=0.83)
boostedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“HbA1c was reported in only one study involving myostatin knockout mice, which demonstrated a relative increase in muscle mass of 53.8–59.5% and a corresponding HbA1c reduction of 2.2–21.8% [61].”
§ Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search > Systematic Literature Analysis to Find Out Whether Muscle Hypertrophy Is Associated with Altered Fat Mass and Glucose Homeostasis > Is Muscle Hypertrophy Associated with Altered Glucose Homeostasis?
What the sources say
- Supportedcites [61] Butcher JT, Mintz JD, Larion S, Qiu S, Ruan L, Fulton DJ, Stepp DW. Increased muscle mass protects against hypertension and renal injury in obesity. J Am Heart Assoc. 2018;7: e009358. https://doi.org/10.1161/JAHA.118.009358. source
Table 1 (Results; page not provided) reports HbA1c of 4.6% versus 4.5% in lean control and myostatin-knockout mice, and 7.8% versus 6.1% in obese control and knockout mice. Those values correspond to relative reductions of approximately 2.2% and 21.8%, respectively. (LLM, conf=0.94)
boostedstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“when patients with overweight or obesity and type 2 diabetes were injected every 4 weeks for 48 weeks with either 10 mg/kg of the myostatin receptor inhibitor bimagrumab versus placebo, lean mass (a proxy for muscle mass) increased by 1.70 kg (80% CI: 1.14 to 2.26 kg)”
§ Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search > Introduction
What the sources say
- Supportedcites [23] Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4: e2033457. https://doi.org/10.1001/jamanetworkopen.2020.33457. source
The Methods (Trial Procedures) report 10 mg/kg bimagrumab or placebo by intravenous infusion every 4 weeks for 48 weeks. The Results (Secondary, Exploratory, and Supportive End Points) report a 1.70 kg lean-mass gain (80% CI, 1.14 to 2.26 kg) in the bimagrumab group, compared with a 0.4 kg loss in the placebo group. The 1.70 kg figure is the change within the bimagrumab group, not the placebo-adjusted difference. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and HbA1c dropped by 0.76% (80% CI: −1.05 to −0.48%) [23].”
§ Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search > Introduction
What the sources say
- Supportedcites [23] Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4: e2033457. https://doi.org/10.1001/jamanetworkopen.2020.33457. source
Table 2 (Results, Primary Efficacy End Point) reports an HbA1c change of −0.76 percentage points in the bimagrumab group, with an 80% CI of −1.05 to −0.48. The Discussion also describes this as a decrease after 48 weeks of treatment. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“fat mass dropped by 7.49 kg (80% CI: −8.33 to −6.64 kg)”
§ Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search > Introduction
What the sources say
- Supportedcites [23] Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4: e2033457. https://doi.org/10.1001/jamanetworkopen.2020.33457. source
Table 2 in Results > Primary Efficacy End Point reports a 7.49 kg decrease in fat mass in the bimagrumab group, with an 80% CI of −8.33 to −6.64 kg. This is the within-group change, not the placebo-adjusted difference of −7.31 kg. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
106 more claims · 18 with their cited sources checked
Create a free account to see all 150 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 13
Citations
Cites
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“In an opinion in the Journal of Physiology [209], we have recently argued that the bimagrumab effects in patients with obesity are preferable to those of, e.g., semaglutide because the fat loss is not associated with muscle atrophy, as is the case with semaglu-tide treatment [210].”
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792 · cited 1×
“This difference spans the diagnostic boundary between diabetes mellitus (≥ 126 mg/dL) and prediabetes ( 126 mg/dL) [195].”
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416 · cited 1×
“This should not come as a surprise, given that almost 100 years ago, Otto Warburg demonstrated that sarcomas, which are a growing tissue like hypertrophying muscle take up glucose at a high rate [179].”
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“Lifestyle modification includes a healthy and hypocaloric diet to limit hyperglycaemic periods and regular exercise [9].”
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143 · cited 1×
“Elevated circulating branched-chain amino acids are an established risk marker for the development of type 2 diabetes mellitus [192].”
Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr
Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.81 · Cited by 3,087 · cited 2×
“Exercise itself, independent of muscle hypertrophy, can potentially reduce fat mass and improve glucose homeostasis by increasing energy expenditure, enhancing insulin sensitivity, and stimulating glucose uptake via contraction-mediated pathways [25–27].”
Research works printed but not linked: 2
- WHO. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020.
- Cavalie H, Mounier R, Clottes E, Bricout V, Lac G. Clenbuterol treatment differently affects muscle in exercised or sedentary rats. J Exerc Physiol Online. 2004;7:111–20.
Cited by
Fuentes-Barría, H., Aguilera-Eguía, R. A., Flores-Fernández, C., Angarita, L., & Alarcón-Rivera, M. (2026) · Biomedicines · doi:10.3390/biomedicines14040752 · Cited by 22
Glycolytic metabolism and biomass production from glucose in human skeletal muscle growth
Mäntyselkä, S., Ahvenlammi, M., Vartiainen, J., Halonen, E. J., Kolari, K., Wackerhage, H., Permi, P., Varjosalo, M. T., Kelahaara, M., Ahtiainen, J. P., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00525.2025 · Cited by 10
Self-citationAgbaje, A. O. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101437 · Cited by 3
“Moreover, the DXA-direct measure of body composition identified increased lean mass metabolic health benefits in decreasing the risk of excess adiposity, insulin resistance, and type 2 diabetes in both young and adult populations, previously obscured by BMI assessment [9,10].”
InfluentialWan, J., Huang, X., Zou, Y., Sheng, G., Xie, G., & Zhang, N. (2025) · European journal of medical research · doi:10.1186/s40001-025-03564-6 · Cited by 5
Longitudinal Insights Into Pediatric Hypertension, Cardiac Consequences, and Physical Activity
Corsi, D. R., & Agbaje, A. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01370-x · Cited by 2
“A 2.6% increase in global muscle mass in humans has been associated with several metabolic improvements, such as lower fat mass, hemoglobin A1c, and fasting glucose level reduction; however, the cardiovascular response to increased muscle mass is paradoxical [62, 63].”
Influential
Metadata
- Authors
- Havers, T., Held, S., Schönfelder, M., Geisler, S., & Wackerhage, H.
- Affiliations
- Technical University of Munich (DE)
- Corresponding author
- Havers, Tim
- Venue
- Sports Medicine
- Published
- 2025-06-27
- Volume
- 55
- Issue
- 8
- Pages
- 1867-1885
- ISSN
- 0112-1642 (ISSN-L)
- 1179-2035
- PMC
- PMC12460530
- OpenAlex
- W4411687406
- Cited by
- 19
- References
- 226
- Citations by year
- 2026: 17 · 2025: 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Sports Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Funders
- Technische Universität München
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- skeletal muscle hypertrophy, fat mass, glucose homeostasis, obesity, type 2 diabetes, overweight, resistance training, HbA1c, fasting blood glucose
- MeSH terms
- Skeletal Muscle Enlargement, Adipose Tissue, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Glucose, Glycated Hemoglobin, Homeostasis, Humans, Hypertrophy, Obesity, Muscle, Skeletal, Resistance Training
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search. https://app.cochat.ai/papers/10.1007/s40279-025-02263-w
- The paper
- Havers, T., Held, S., Schönfelder, M., Geisler, S., & Wackerhage, H. (2025). Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search. Sports Medicine. https://doi.org/10.1007/s40279-025-02263-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.